The ad watchdog flagged the drug maker for what it said was yet another misleading Ampyra promotional piece.
Business briefs: Teva, AbbVie, Novartis, Wockhardt
July 24, 2013
7:13 pm
FDA grants Teva three years exclusivity to sell Plan B OTC for all ages; FDA gives Humira a thumbs-down for spondyloarthritis; a UK vaccine committee rejects Novartis’ meningitis B shot; and Wockhardt gets a warning letter from FDA for its manufacturing practices at an Indian plant.
Business briefs: PwC, Novartis, iDoc24, FDA
April 10, 2013
4:44 pm
PricewaterhouseCoopers says consumers are talking healthcare, but not about the good stuff; Novartis shuffles 120 Texas jobs; 73% of STD app queries came from men last month; FDA is keeping very busy; and OgilvyCommonhealth hires a consumer head
AMARC Angst: Has FDA put pharma Facebook “Likes” in the crosshairs?
The FDA has issued a rare untitled letter concerning a pitch letter – a reminder that the agency does not consider press materials to be exempted from its oversight.
FDA’s Office of Prescription Drug Promotion issued a warning letter to Mylan and Pfizer for an EpiPen TV ad that the agency said hyped the effectiveness of the drug.
Pfizer’s Lipitor website touted the efficacy of Caduet, Chantix and Norvasc but failed to balance those claims with risk info for the drugs, according to an “untitled letter” from FDA’s Division of Drug Marketing, Advertising and Communication (DDMAC).
The FDA’s Division of Drug Marketing, Advertising and Communications has written 26% more enforcement letters to drug companies over promotional practices this year than it did in 2009.